affsans résumé
Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1–7 trials2019· review· en· Diabetes & Metabolism· Medicine
282
citations